ADC Therapeutics Q3 Product Revenue Totals $21 Million as Loss Narrows
ADC Therapeutics reported third-quarter 2026 results on November 9, 2026, with net product revenue rising to $21.0 million from $15.8 million a year earlier, primarily on higher volume. Net loss narrowed to $25.3 million from $41.0 million as operating expenses fell, while an October 2026 restructuring reduced debt and added equity financing. Lower Research Spending Narrows the Loss Total operating expenses declined 24% to $36.1 million from $47.4 million. Research and development expense fell…